EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access

Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis

Jena L Miller, Ahmet A Baschat, Mara Rosner, Yair J Blumenfeld, Julie S Moldenhauer, Anthony Johnson, Mauro H Schenone, Michael V Zaretsky, Ramen H Chmait, Juan M Gonzalez, Russell S Miller, Anita J Moon-Grady und 11 weitere

JAMA · 05.12.2023 · 330 (21) · 2096

DOI: 10.1001/jama.2023.21153 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JAMA, erschienen am 05.12.2023. Verfasst von Jena L Miller und 22 weiteren Autor:innen. Beteiligte Einrichtung: Center for Fetal Therapy, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland. Hauptthemen laut MEDLINE: Lung Diseases, Fetal Therapies, Isotonic Solutions, Kidney Diseases. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Early anhydramnios during pregnancy, resulting from fetal bilateral renal agenesis, causes lethal pulmonary hypoplasia in neonates. Restoring amniotic fluid via serial amnioinfusions may promote lung development, enabling survival.

Objective

To assess neonatal outcomes of serial amnioinfusions initiated before 26 weeks’ gestation to mitigate lethal pulmonary hypoplasia. Design, Setting, and Participants Prospective, nonrandomized clinical trial conducted at 9 US fetal therapy centers between December 2018 and July 2022. Outcomes are reported for 21 maternal-fetal pairs with confirmed anhydramnios due to isolated fetal bilateral renal agenesis without other identified congenital anomalies. Exposure Enrolled participants initiated ultrasound-guided percutaneous amnioinfusions of isotonic fluid before 26 weeks’ gestation, with frequency of infusions individualized to maintain normal amniotic fluid levels for gestational age. Main Outcomes and Measures The primary end point was postnatal infant survival to 14 days of life or longer with dialysis access placement.

Results

The trial was stopped early based on an interim analysis of 18 maternal-fetal pairs given concern about neonatal morbidity and mortality beyond the primary end point despite demonstration of the efficacy of the intervention. There were 17 live births (94%), with a median gestational age at delivery of 32 weeks, 4 days (IQR, 32-34 weeks). All participants delivered prior to 37 weeks’ gestation. The primary outcome was achieved in 14 (82%) of 17 live-born infants (95% CI, 44%-99%). Factors associated with survival to the primary outcome included a higher number of amnioinfusions ( P = .01), gestational age greater than 32 weeks ( P = .005), and higher birth weight ( P = .03). Only 6 (35%) of the 17 neonates born alive survived to hospital discharge while receiving peritoneal dialysis at a median age of 24 weeks of life (range, 12-32 weeks). Conclusions and Relevance Serial amnioinfusions mitigated lethal pulmonary hypoplasia but were associated with preterm delivery. The lower rate of survival to discharge highlights the additional mortality burden independent of lung function. Additional long-term data are needed to fully characterize the outcomes in surviving neonates and assess the morbidity and mortality burden. Trial Registration ClinicalTrials.gov Identifier: NCT03101891

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung DiseasesFetal TherapiesIsotonic SolutionsKidney DiseasesOligohydramniosGestational AgePregnancy OutcomeFetal DiseasesFemaleProspective StudiesInfusions, ParenteralKidneyUltrasonography, InterventionalTreatment OutcomeInfant, NewbornInfantPregnancyHumansPremature BirthCongenital AbnormalitiesAbnormalities, MultipleLung

Substanzen

Isotonic Solutions

Autor:innen und Institutionen

  • Center for Fetal Therapy, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland.
  • Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California.
  • Center for Fetal Diagnosis and Treatment, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • The Fetal Center, Department of Obstetrics and Gynecology, University of Texas Health Center, Houston.
  • Division of Maternal and Fetal Medicine, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota.
  • Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora.

Förderung

  • NICHD NIH HHS

Zitieren

APA

Miller, J. L., Baschat, A. A., Rosner, M., Blumenfeld, Y. J., Moldenhauer, J. S., Johnson, A., Schenone, M. H., Zaretsky, M. V., Chmait, R. H., Gonzalez, J. M., Miller, R. S., Moon-Grady, A. J., Bendel-Stenzel, E., Keiser, A. M., Avadhani, R., Jelin, A. C., Davis, J. M., Warren, D. S., Hanley, D. F., …, & Atkinson, M. A. (2023). Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis. JAMA, 330(21), 2096. https://doi.org/10.1001/jama.2023.21153

Vancouver

Miller JL, Baschat AA, Rosner M, Blumenfeld YJ, Moldenhauer JS, Johnson A, et al. Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis. JAMA. 2023;330(21):2096. doi:10.1001/jama.2023.21153

BibTeX
@article{Miller2023,
  author = {Miller, Jena L and Baschat, Ahmet A and Rosner, Mara and Blumenfeld, Yair J and Moldenhauer, Julie S and Johnson, Anthony and Schenone, Mauro H and Zaretsky, Michael V and Chmait, Ramen H and Gonzalez, Juan M and Miller, Russell S and Moon-Grady, Anita J and Bendel-Stenzel, Ellen and Keiser, Amaris M and Avadhani, Radhika and Jelin, Angie C and Davis, Jonathan M and Warren, Daniel S and Hanley, Daniel F and Watkins, Joslynn A and Samuels, Joshua and Sugarman, Jeremy and Atkinson, Meredith A},
  title = {Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {21},
  pages = {2096},
  doi = {10.1001/jama.2023.21153}
}
Kostenlos starten →